Table 1:
Clinical and pathological characteristics of CDK12-altered and CDK12-WT prostate cancer patients
| CDK12-altered | CDK12-WT | |
|---|---|---|
| Number of patients | 100 | 1365 |
| Age at diagnosis - years | ||
| Median (IQR) | 61 (54–67) | 63 (56–68) |
| Histology at diagnosis - n (% of known cases) | ||
| Adenocarcinoma | 94 (97) | 1216 (99) |
| Adenocarcinoma with neuroendocrine features | 2 (2) | 12 (0.9) |
| Other | 1 (1) | 6 (0.4) |
| Unknown | 3 | 131 |
| PSA at diagnosis - ng/mL | ||
| Median (IQR) | 14.8 (7.7–77.8) | 9.0 (5.3–24.1) |
| Gleason - n (% of known cases) | ||
| 6 | 7 (8) | 108 (9) |
| 7 | 10 (12) | 435 (34) |
| ≥8 | 68 (80) | 727 (57) |
| Not evaluable | 15 | 95 |
| Metastatic at diagnosis - n (% of known cases) | 39 (40) | 346 (26) |
| Unknown | 2 | 23 |
| Sites of metastasis at tissue collection - n (% of total metastatic patients) | ||
| Bone | 48 (60) | 528 (57) |
| Nonregional lymph nodes | 44 (55) | 380 (41) |
| Liver | 5 (6.3) | 93 (10) |
| Lung | 4 (5) | 101 (11) |
| Visceral | 7 (8.8) | 165 (18) |